Systemic markers of oxidative status and colorectal adenomatous polyps.
OBJECTIVE
Oxidative damage has been implicated in carcinogenesis. We hypothesized that elevated systemic oxidative status would be associated with later occurrence of colorectal adenomatous polyps, a precursor of colorectal cancer.


METHODS
We examined the prospective association between four systemic markers of oxidative status and colorectal adenomatous polyps within a nondiabetic subcohort of the Insulin Resistance Atherosclerosis Study (n = 425). Urine samples were collected from 1992 to 1994 and colorectal adenomas prevalence were assessed in 2002 to 2004. Oxidative status markers were assessed, which included four F(2)-isoprostanes (F(2)-IsoPs) from the classes III and IV: iPF2α-III, 2,3-dinor-iPF2α-III (a metabolite of iPF2α-III), iPF2α-VI, and 8,12-iso-iPF2α-VI. All biomarkers were quantified using liquid chromatography-tandem mass spectrometry. Prospective associations were assessed using multivariate logistic regression analysis.


RESULTS
The adjusted odds ratio (OR) (95% confidence interval [CI]) for occurrence of colorectal adenomatous polyps and scaled to 1 SD of F(2)-IsoP distribution were 1.16 (95% CI, 0.88-1.50), 0.88 (95% CI, 0.63-1.17), 1.04 (95% CI, 0.80-1.34), and 1.16 (95% CI, 0.90-1.48) for iPF2α-III, iPF2α-VI, 8,12-iso-iPF2α-VI, and 2,3-dinor-iPF2α-III, respectively.


CONCLUSIONS
The lack of association between F(2)-IsoPs and adenomatous polyps does not support the hypothesis that elevated oxidative status is associated with colorectal adenomatous polyp occurrence during a 10-year period of follow-up.
Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Sharareh
S
Siamakpour-Reihani
Peter M
PM
Scarbrough
Frances
F
Wang
Ivan
I
Spasojevic
Karel
K
Base
Rebecca
R
Sedjo
Ralph B
RB
D'Agostino
Dora
D
Il'yasova
D018256:Adenomatous Polyps / Q000175:diagnosis / Q000453:epidemiology / Q000652:urine*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000652:urine*; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000652:urine*; D015897:Comorbidity; D028441:F2-Isoprostanes / Q000652:urine*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000453:epidemiology; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011230:Precancerous Conditions / Q000175:diagnosis / Q000453:epidemiology / Q000652:urine*; D015995:Prevalence; D012907:Smoking / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor; D028441:F2-Isoprostanes